arrow
G

Gregory L. Moore

xencor, inc.
H指数:19
被引数:1,741

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability

一项基于实验亲和力与可开发性的模拟抗体发现的盲法前瞻性基准研究

2026-08-190
OA
A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies
2024-11-061
OAAI
JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

JNJ-87801493 (CD20xCD28),一种潜在的首创CD20靶向CD28共刺激双特异性抗体,增强了B细胞靶向T细胞结合剂在预临床模型中的活性。

BLOOD
IF23.1
2024-11-050
PRE
Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
2023-04-040
PRE
AMG 509, A STEAP1 X CD3 BISPECIFIC XMAB® 2+1 IMMUNE THERAPY, EXHIBITS AVIDITY-DRIVEN BINDING AND PREFERENTIAL KILLING OF HIGH STEAP1-EXPRESSING PROSTATE AND EWING SARCOMA CANCER CELLS
2020-11-092
PREAI
Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors
2017-07-0112
PRE
Immunotherapy with anti-PSMA x anti-CD3 bispecific antibody stimulates potent killing of a human prostate cancer cell line and target mediated T cell activation in monkeys: A potential therapy for prostate cancer
2016-07-151
PRE
Immune suppression in cynomolgus monkeys by XPro9523 An improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn

XPro9523对食蟹猴的免疫抑制作用与CD80,CD86和新生儿Fc受体FcRn的结合增强的CTLA4-Ig融合

MABS
IF7.3
2014-10-2726
OAAI